Supply Chain Pulse — 2026-07-29

Boston Scientific is launching a restructuring program carrying a price tag of $700M–$800M and up to $300M in employee termination benefits, with the overhaul running through the end of 2029. For supply chain teams, a multi-year restructuring at a major device manufacturer is a red flag worth monitoring: product line rationalization, manufacturing footprint shifts, and sales force reductions can all translate into allocation changes, longer lead times, or discontinued SKUs with little warning. Pair that with a separate story today showing GLP-1 drugs are measurably shrinking bariatric surgery volumes — and you have a clear signal that device demand forecasting is getting harder from both the supply and the demand side. If Boston Scientific is in your top-tier vendor portfolio, now is the time to open a conversation with your rep about pipeline continuity — before the org chart changes make finding the right contact a project in itself.

Quick Hits

• Kettering Health and Knox Community Hospital have proposed a combination — another regional health system consolidation that could reshape local contracting leverage and GPO alignment for both organizations. (Modern Healthcare)

Boston Scientific Launches $700M–$800M Global Restructuring, Cutting Headcount Through 2029

Boston Scientific has announced a sweeping restructuring initiative expected to cost between $700M and $800M in total, including up to $300M earmarked specifically for employee termination benefits, with completion targeted by end of 2029. For hospital and ASC supply chain leaders, a four-plus-year restructuring at a top-tier device supplier raises legitimate concerns about product portfolio continuity, manufacturing site consolidation, and potential service disruptions. Now is the moment to audit your Boston Scientific spend, flag any sole-source dependencies, and request a formal business continuity briefing from your account team.

Source: Medical Device Network

GLP-1 Drugs Are Shrinking Bariatric Surgery Volumes — and Your Device Forecasts

A new analysis confirms that the rapid uptake of GLP-1 receptor agonists like semaglutide has produced a measurable decline in bariatric surgery procedures across multiple markets, a trend with direct implications for surgical supply and device utilization planning. OR supply managers relying on historical bariatric case volumes to project stapler, retractor, and related consumable needs should treat those baselines as increasingly unreliable. The GLP-1 effect is likely to deepen before it stabilizes — build that assumption into your next contract negotiation and your FY2027 demand plan.

Source: Medical Device Network

You're receiving this because you subscribed to Supply Chain Pulse, a daily brief for healthcare supply chain professionals. Unsubscribe